Rupintrivir - Experimental Treatment for the Common Cold
Key Data:
Drug (Brand / Generic)
Rupintrivir (AG7088)
Company/Licensee
Agouron Pharmaceuticals (Pfizer subsidiary)
Therapy Class
Anti-viral agent
Product Description
Protease inhibitor
Current Indication
Treatment of colds due to rhinovirus infection
Market Sector
Anti-infectives
Development Status
Further development halted after failure in Phase II trials
